Fouad Madhi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fouad Madhi has a total of 306 co-authors. Here are the top co-authors by number of shared publications:
Robert Cohen
Groupe de Pathologie Infectieuse Pédiatrique (GPIP) de la Société Française de Pédiatrie (SFP) , Paris , France
11 shared publicationsSandra Biscardi
Pediatric Infectious Pathology Group of the French Pediatric Society (GPIP), France; Pediatric Emergency, Centre Hospitalier Intercommunal de Créteil, Créteil, France
9 shared publications- Corinne Levy
ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France
7 shared publications - Robert Cohen
ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Saint Maur-des-Fossés, France
7 shared publications Emmanuel Grimprel
Pediatric Infectious Pathology Group of the French Pediatric Society (GPIP), France; University of Paris 6, Department of Pediatrics, Trousseau Hospital, Paris, France
5 shared publicationsStéphane Bonacorsi
Groupe de Pathologie Infectieuse Pédiatrique (GPIP) de la Société Française de Pédiatrie (SFP) , Paris , France
5 shared publications
Latest Publications
- Open Access
- 28 February 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (7) , 599-608
Blood Parechovirus RT-PCR Testing in Neonates and Infants: Comparison of Clinical and Biologic Features With Those of Enterovirus Infections
Background: To assess human parechovirus (HPeV) detection by real-time polymerase chain reaction in blood with or without cerebrospinal fluid samples in neonates and infants and compare the clinical and biological characteristics of HPeV patients with those of patients with or without enterovirus (EV) infection. Methods: In all, 92 HPeV-infected patients (40 newborns and 52 infants) presenting with fever without source, sepsis-like disease or suspected meningitis were evaluated in 2 French hospitals from 2007 to 2018. The clinical and biological characteristics of HPeV patients were compared with those of 100 EV-infected patients and of 95 control patients with fever without source or sepsis-like disease. Results: HPeV was detected more frequently in blood [100% (51/51)] than in cerebrospinal fluid specimens [89% (67/75), P = 0.02]. Genotyping identified HPeV3 in 76/85 (89%) positive specimens. HPeV-infected patients were more likely than EV-infected or control patients to have sepsis-like disease and required more frequent vascular filling (39% in newborns and 26% in infants) and empirical antibiotics (91% in newborns and 69% in infants). HPeV patients had lower peripheral white blood cell counts and lower lymphocyte levels (P = 0.002) and longer lengths of hospital stay than EV or control patients (P = 0.03). A white blood cell count 9/L can be helpful in differentiating HPeV patients from control patients. Conclusions: Detection of HPeV should be part of the differential diagnosis of EV infections. The use of small automata to perform real-time polymerase chain reaction assays in emergency units should allow faster diagnosis and, if the result is positive, avoid prolonged length of hospital stay and unnecessary administration of antibiotics in patients without virus-bacteria co-infection.
- 28 February 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (7) , 599-608
Open AccessBlood Parechovirus RT-PCR Testing in Neonates and Infants: Comparison of Clinical and Biologic Features With Those of Enterovirus Infections
Background: To assess human parechovirus (HPeV) detection by real-time polymerase chain reaction in blood with or without cerebrospinal fluid samples in neonates and infants and compare the clinical and biological characteristics of HPeV patients with those of patients with or without enterovirus (EV) infection. Methods: In all, 92 HPeV-infected patients (40 newborns and 52 infants) presenting with fever without source, sepsis-like disease or suspected meningitis were evaluated in 2 French hospitals from 2007 to 2018. The clinical and biological characteristics of HPeV patients were compared with those of 100 EV-infected patients and of 95 control patients with fever without source or sepsis-like disease. Results: HPeV was detected more frequently in blood [100% (51/51)] than in cerebrospinal fluid specimens [89% (67/75), P = 0.02]. Genotyping identified HPeV3 in 76/85 (89%) positive specimens. HPeV-infected patients were more likely than EV-infected or control patients to have sepsis-like disease and required more frequent vascular filling (39% in newborns and 26% in infants) and empirical antibiotics (91% in newborns and 69% in infants). HPeV patients had lower peripheral white blood cell counts and lower lymphocyte levels (P = 0.002) and longer lengths of hospital stay than EV or control patients (P = 0.03). A white blood cell count 9/L can be helpful in differentiating HPeV patients from control patients. Conclusions: Detection of HPeV should be part of the differential diagnosis of EV infections. The use of small automata to perform real-time polymerase chain reaction assays in emergency units should allow faster diagnosis and, if the result is positive, avoid prolonged length of hospital stay and unnecessary administration of antibiotics in patients without virus-bacteria co-infection.
- 18 September 2023
- Published by Elsevier in Infectious Diseases Now
- Vol. 53 (8) , 104786
Antimicrobial treatment of urinary tract infections in children
- 18 September 2023
- Published by Elsevier in Infectious Diseases Now
- Vol. 53 (8) , 104786
Antimicrobial treatment of urinary tract infections in children
- 18 September 2023
- Published by Elsevier in Infectious Diseases Now
- Vol. 53 (8) , 104785
Antimicrobial treatment of ENT infections
- 18 September 2023
- Published by Elsevier in Infectious Diseases Now
- Vol. 53 (8) , 104785
Antimicrobial treatment of ENT infections
- 15 September 2023
- Published by Elsevier in Infectious Diseases Now
- Vol. 53 (8) , 104780
The principles of curative antibiotic treatments
- 15 September 2023
- Published by Elsevier in Infectious Diseases Now
- Vol. 53 (8) , 104780
The principles of curative antibiotic treatments
- 13 September 2023
- Published by Elsevier in Infectious Diseases Now
- Vol. 53 (8) , 104782
Antimicrobial treatment of lower respiratory tract infections in children
- 13 September 2023
- Published by Elsevier in Infectious Diseases Now
- Vol. 53 (8) , 104782
Antimicrobial treatment of lower respiratory tract infections in children
- Open Access
- 2 March 2023
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 5 (2) , dlad042
Meningitis caused by extended-spectrum β-lactamase-producingEscherichia coliin infants in France: a case series
We report the first case series focusing on clinical and biological characteristics of meningitis caused by ESBL-producing Escherichia coli in infants. Between 2001 and 2020, data on all cases of E. coli meningitis were prospectively collected from a network of 259 paediatric wards and 168 microbiology laboratories in France. We analysed the clinical and biological characteristics, short-term complications and long-term sequelae of ESBL-producing E. coli meningitis cases in patients E. coli paediatric meningitis were reported. ESBL-producing E. coli represented 12 (2.2%) cases. We included 10 patients aged E. coli meningitis in children and needs to be given as early as possible (<48 h) and for at least 21 days. Maternal colonization or infection with ESBL-producing Enterobacteriaceae needs to be reported to the neonatal or paediatric ICU team, in order to adapt the empirical antibiotic therapy.
- 2 March 2023
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 5 (2) , dlad042
Open AccessMeningitis caused by extended-spectrum β-lactamase-producingEscherichia coliin infants in France: a case series
We report the first case series focusing on clinical and biological characteristics of meningitis caused by ESBL-producing Escherichia coli in infants. Between 2001 and 2020, data on all cases of E. coli meningitis were prospectively collected from a network of 259 paediatric wards and 168 microbiology laboratories in France. We analysed the clinical and biological characteristics, short-term complications and long-term sequelae of ESBL-producing E. coli meningitis cases in patients E. coli paediatric meningitis were reported. ESBL-producing E. coli represented 12 (2.2%) cases. We included 10 patients aged E. coli meningitis in children and needs to be given as early as possible (<48 h) and for at least 21 days. Maternal colonization or infection with ESBL-producing Enterobacteriaceae needs to be reported to the neonatal or paediatric ICU team, in order to adapt the empirical antibiotic therapy.
- Open Access
- 21 May 2022
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 4 (3) , dlac056
Comparative genomic analysis of ESBL-producing Escherichia coli from faecal carriage and febrile urinary tract infection in children: a prospective multicentre study
The reliability of ESBL-producing Escherichia coli (ESBL-Ec) faecal carriage monitoring to guide probabilistic treatment of febrile urinary tract infection (FUTI) in children remains unclear. To compare the genomic characteristics of ESBL-Ec isolates from faecal carriage and FUTI to assess their correlation and identify a FUTI-associated virulence profile. We conducted a prospective multicentre hospital and ambulatory-based study. We analysed the genotypes and virulence factors of both faecal and FUTI ESBL-Ec by whole genome sequencing. Correlations were assessed by non-parametric Spearman coefficient and virulence factors were assessed by chi-squared tests with Bonferroni correction. We included 218 ESBL-Ec causing FUTI and 154 ESBL-Ec faecal carriage isolates. The most frequent ST was ST131 (44%) in both collections. We found high correlation between carriage and ESBL-Ec FUTI regarding genes/alleles (rho = 0.88, P < 0.0001) and combinations of virulence genes, MLST and serotypes (rho = 0.90, P < 0.0001, rho = 0.99, P = 0.0003, rho = 0.97, P = 0.005 respectively). Beside this strong correlation, we found five genes that were significantly associated with FUTI (papC, papGII, hlyC, hek and traJ). The strongest association with FUTI was found with adhesin gene allele papGII (54% in FUTI versus 16% in carriage) and for papGII and gene traJ alone or in combination (63% versus 24%). The genomic profile of ESBL-Ec causing FUTI in children strongly correlates with faecal carriage isolates except for a few genes. The presence of papGII and/or traJ in a previously identified carriage strain could be used as a marker of uropathogenicity and may guide the empirical antimicrobial choice in subsequent FUTI.
- 21 May 2022
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 4 (3) , dlac056
Open AccessComparative genomic analysis of ESBL-producing Escherichia coli from faecal carriage and febrile urinary tract infection in children: a prospective multicentre study
The reliability of ESBL-producing Escherichia coli (ESBL-Ec) faecal carriage monitoring to guide probabilistic treatment of febrile urinary tract infection (FUTI) in children remains unclear. To compare the genomic characteristics of ESBL-Ec isolates from faecal carriage and FUTI to assess their correlation and identify a FUTI-associated virulence profile. We conducted a prospective multicentre hospital and ambulatory-based study. We analysed the genotypes and virulence factors of both faecal and FUTI ESBL-Ec by whole genome sequencing. Correlations were assessed by non-parametric Spearman coefficient and virulence factors were assessed by chi-squared tests with Bonferroni correction. We included 218 ESBL-Ec causing FUTI and 154 ESBL-Ec faecal carriage isolates. The most frequent ST was ST131 (44%) in both collections. We found high correlation between carriage and ESBL-Ec FUTI regarding genes/alleles (rho = 0.88, P < 0.0001) and combinations of virulence genes, MLST and serotypes (rho = 0.90, P < 0.0001, rho = 0.99, P = 0.0003, rho = 0.97, P = 0.005 respectively). Beside this strong correlation, we found five genes that were significantly associated with FUTI (papC, papGII, hlyC, hek and traJ). The strongest association with FUTI was found with adhesin gene allele papGII (54% in FUTI versus 16% in carriage) and for papGII and gene traJ alone or in combination (63% versus 24%). The genomic profile of ESBL-Ec causing FUTI in children strongly correlates with faecal carriage isolates except for a few genes. The presence of papGII and/or traJ in a previously identified carriage strain could be used as a marker of uropathogenicity and may guide the empirical antimicrobial choice in subsequent FUTI.
- Open Access
- 16 September 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0257217
Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase–producing Enterobacteriaceae in children: A French multicenter study
We need studies assessing therapeutic options for oral relay in febrile urinary tract infection (FUTI) due to ESBL–producing Enterobacteriaceae (ESBL-E) in children. Amoxicillin-clavulanate/cefixime (AC-cefixime) combination seems to be a suitable option. We sought to describe the risk of recurrence at 1 month after the end of treatment for FUTI due to ESBL-E according to the oral relay therapy used. We retrospectively identified children <18 years who were included in a previous prospective observational multicentric study on managing FUTI due to ESBL-E between 2014 and 2017 in France. We collected whether children who received cotrimoxazole, ciprofloxacin or the AC-cefixime combination as the oral relay therapy reported a recurrence within the first month after the end of treatment. Then, we analyzed the susceptibility drug-testing of the strains involved. We included 199 children who received an oral relay therapy with cotrimoxazole (n = 72, 36.2%), ciprofloxacin (n = 38, 19.1%) or the AC-cefixime combination (n = 89, 44.7%). Nine (4.5%) patients had a recurrence within the first month after the end of treatment, with no difference between the 3 groups of oral relay (p = 0.8): 4 (5.6%) cotrimoxazole, 2 (5.3%) ciprofloxacin and 3 (3.4%) AC-cefixime combination. Phenotype characterization of 249 strains responsible for FUTI due to ESBL-E showed that 97.6% were susceptible to the AC-cefixime combination. The AC-cefixime combination represents an interesting therapeutic option for oral relay treatment of FUTI due to ESBL-E as the recurrence rate at 1 month after the end of treatment was the same when compared to cotrimoxazole and ciprofloxacin.
- 16 September 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0257217
Open AccessRelay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase–producing Enterobacteriaceae in children: A French multicenter study
We need studies assessing therapeutic options for oral relay in febrile urinary tract infection (FUTI) due to ESBL–producing Enterobacteriaceae (ESBL-E) in children. Amoxicillin-clavulanate/cefixime (AC-cefixime) combination seems to be a suitable option. We sought to describe the risk of recurrence at 1 month after the end of treatment for FUTI due to ESBL-E according to the oral relay therapy used. We retrospectively identified children <18 years who were included in a previous prospective observational multicentric study on managing FUTI due to ESBL-E between 2014 and 2017 in France. We collected whether children who received cotrimoxazole, ciprofloxacin or the AC-cefixime combination as the oral relay therapy reported a recurrence within the first month after the end of treatment. Then, we analyzed the susceptibility drug-testing of the strains involved. We included 199 children who received an oral relay therapy with cotrimoxazole (n = 72, 36.2%), ciprofloxacin (n = 38, 19.1%) or the AC-cefixime combination (n = 89, 44.7%). Nine (4.5%) patients had a recurrence within the first month after the end of treatment, with no difference between the 3 groups of oral relay (p = 0.8): 4 (5.6%) cotrimoxazole, 2 (5.3%) ciprofloxacin and 3 (3.4%) AC-cefixime combination. Phenotype characterization of 249 strains responsible for FUTI due to ESBL-E showed that 97.6% were susceptible to the AC-cefixime combination. The AC-cefixime combination represents an interesting therapeutic option for oral relay treatment of FUTI due to ESBL-E as the recurrence rate at 1 month after the end of treatment was the same when compared to cotrimoxazole and ciprofloxacin.
- 28 August 2021
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 76 (11) , 2839-2846
Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections
Objectives: Oral treatment of febrile urinary tract infections (FUTIs) can be impaired by MDR Enterobacterales often combining ESBL and inhibitor-resistant genes. We studied the impact of β-lactamases and Enterobacterales’ genotypes on the cefixime, cefpodoxime and mecillinam ± amoxicillin/clavulanate MICs. Materials and methods: In this multicentric study, we included 251 previously whole-genome-sequenced ESBL-producing Enterobacterales, isolated in French children with FUTIs. The MICs of cefixime, cefpodoxime, mecillinam alone and combined with amoxicillin/clavulanate were determined and analysed with respect to genomic data. We focused especially on the isolates’ ST and their type of β-lactamases. Clinical outcomes of patients who received cefixime + amoxicillin/clavulanate were also analysed. Results: All isolates were cefixime and cefpodoxime resistant. Disparities depending on blaCTX-M variants were observed for cefixime. The addition of amoxicillin/clavulanate restored susceptibility for cefixime and cefpodoxime in 97.2% (MIC50/90 of 0.38/0.75 mg/L) and 55.4% (MIC50/90 of 1/2 mg/L) of isolates, respectively, whatever the ST, the blaCTX-M variants or the association with inhibitor-resistant β-lactamases (34.2%). All isolates were susceptible to mecillinam + amoxicillin/clavulanate with MIC50/90 of 0.19/0.25 mg/L, respectively. Neither therapeutic failure nor any subsequent positive control urine culture were reported for patients who received cefixime + amoxicillin/clavulanate as an oral relay therapy (n = 54). Conclusions: Despite the frequent association of ESBL genes with inhibitor-resistant β-lactamases, the cefixime + amoxicillin/clavulanate MICs remain low. The in vivo efficacy of this combination was satisfying even when first-line treatment was ineffective. Considering the MIC distributions and pharmacokinetic parameters, mecillinam + amoxicillin/clavulanate should also be an alternative to consider when treating FUTIs in children.
- 28 August 2021
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 76 (11) , 2839-2846
Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections
Objectives: Oral treatment of febrile urinary tract infections (FUTIs) can be impaired by MDR Enterobacterales often combining ESBL and inhibitor-resistant genes. We studied the impact of β-lactamases and Enterobacterales’ genotypes on the cefixime, cefpodoxime and mecillinam ± amoxicillin/clavulanate MICs. Materials and methods: In this multicentric study, we included 251 previously whole-genome-sequenced ESBL-producing Enterobacterales, isolated in French children with FUTIs. The MICs of cefixime, cefpodoxime, mecillinam alone and combined with amoxicillin/clavulanate were determined and analysed with respect to genomic data. We focused especially on the isolates’ ST and their type of β-lactamases. Clinical outcomes of patients who received cefixime + amoxicillin/clavulanate were also analysed. Results: All isolates were cefixime and cefpodoxime resistant. Disparities depending on blaCTX-M variants were observed for cefixime. The addition of amoxicillin/clavulanate restored susceptibility for cefixime and cefpodoxime in 97.2% (MIC50/90 of 0.38/0.75 mg/L) and 55.4% (MIC50/90 of 1/2 mg/L) of isolates, respectively, whatever the ST, the blaCTX-M variants or the association with inhibitor-resistant β-lactamases (34.2%). All isolates were susceptible to mecillinam + amoxicillin/clavulanate with MIC50/90 of 0.19/0.25 mg/L, respectively. Neither therapeutic failure nor any subsequent positive control urine culture were reported for patients who received cefixime + amoxicillin/clavulanate as an oral relay therapy (n = 54). Conclusions: Despite the frequent association of ESBL genes with inhibitor-resistant β-lactamases, the cefixime + amoxicillin/clavulanate MICs remain low. The in vivo efficacy of this combination was satisfying even when first-line treatment was ineffective. Considering the MIC distributions and pharmacokinetic parameters, mecillinam + amoxicillin/clavulanate should also be an alternative to consider when treating FUTIs in children.
- Open Access
- 28 May 2021
- Published by Springer Nature in Critical Care
- Vol. 25 (1) , 1-5
Factors associated with death in children with purpura fulminans: a French national prospective cohort study
- 28 May 2021
- Published by Springer Nature in Critical Care
- Vol. 25 (1) , 1-5
Open AccessFactors associated with death in children with purpura fulminans: a French national prospective cohort study